| __timestamp | Dynavax Technologies Corporation | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 50829000 |
| Thursday, January 1, 2015 | 22180000 | 57305000 |
| Friday, January 1, 2016 | 37257000 | 116145000 |
| Sunday, January 1, 2017 | 27367000 | 159362000 |
| Monday, January 1, 2018 | 64770000 | 206366000 |
| Tuesday, January 1, 2019 | 74986000 | 228244000 |
| Wednesday, January 1, 2020 | 79256000 | 293355000 |
| Friday, January 1, 2021 | 100156000 | 401715000 |
| Saturday, January 1, 2022 | 131408000 | 459856000 |
| Sunday, January 1, 2023 | 152946000 | 542705000 |
| Monday, January 1, 2024 | 492128000 |
Unleashing insights
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Exelixis, Inc. and Dynavax Technologies Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Exelixis consistently outpaced Dynavax, with its SG&A expenses growing by over 900%, peaking at approximately $543 million in 2023. In contrast, Dynavax's expenses increased by about 760%, reaching around $153 million in the same year. This divergence highlights Exelixis's aggressive expansion strategy compared to Dynavax's more conservative approach. Notably, both companies saw significant jumps in spending post-2020, reflecting broader industry trends towards increased investment in administrative capabilities. These insights provide a window into the strategic priorities of these biotech firms, offering valuable lessons for stakeholders and investors alike.
Breaking Down SG&A Expenses: Pfizer Inc. vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Breaking Down SG&A Expenses: Insmed Incorporated vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Catalent, Inc. or Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
MannKind Corporation and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Galapagos NV
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.